Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus envelope antigen (HBeAg), also known as Hepatitis B e antigen, is a nonparticulate, soluble viral protein encoded by the precore/core gene of the Hepatitis B virus (HBV). It is processed and secreted by infected hepatocytes into the bloodstream during active viral replication, serving as a key clinical marker for high infectivity and viral load. Biologically, HBeAg acts as an immunomodulator that downregulates host innate immune responses, such as Toll-like receptor 2 expression, thereby promoting immune tolerance and facilitating persistent, chronic HBV infection. In clinical practice, HBeAg seroconversion (the loss of HBeAg and appearance of anti-HBe antibodies) is a major therapeutic endpoint indicating transition to a less active phase of infection. While traditional therapies like nucleos(t)ide analogues (e.g., entecavir, tenofovir) and pegylated interferons indirectly reduce HBeAg levels by suppressing viral replication or boosting host immunity, novel therapeutic strategies are being developed to target HBeAg more directly. These include capsid assembly modulators (CpAMs) that cause misassembly of the precore protein to block HBeAg secretion, and RNA interference (RNAi) agents that degrade viral transcripts to silence HBeAg expression.
Inhibition of viral replication and protein expression, leading to HBeAg seroconversion and reduction of viral load. Nucleos(t)ide analogues inhibit HBV DNA polymerase/reverse transcriptase, while pegylated interferons modulate the host immune response to suppress viral replication. Novel capsid assembly modulators (CpAMs) can directly bind to the precore/core protein, causing misassembly and preventing HBeAg secretion. RNA interference (RNAi) therapeutics like JNJ-3989 target HBV transcripts to degrade viral mRNA and inhibit HBeAg expression.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus envelope antigen (HBeAg).